{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T20:32:44Z","timestamp":1793219564586,"version":"4.5.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T00:00:00Z","timestamp":1776988800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Therapies"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.therap.2026.03.004","type":"journal-article","created":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T15:50:25Z","timestamp":1775145025000},"page":"369-379","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Revue syst\u00e9matique de la litt\u00e9rature et \u00e9valuation de l\u2019efficacit\u00e9 des myorelaxants dans les lombalgies aigu\u00ebs selon la m\u00e9thode REB"],"prefix":"10.1016","volume":"81","author":[{"given":"H\u00e9l\u00e8ne","family":"Langelier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-6533-364X","authenticated-orcid":false,"given":"Julio","family":"Pires","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R\u00e9my","family":"Boussageon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.therap.2026.03.004_bib0170","unstructured":"INRS. Lombalgie. Statistique - Risques. 2018 https:\/\/www.inrs.fr\/risques\/lombalgies\/statistique.html. [Consult\u00e9 le 31\u00a0mars 2026]."},{"key":"10.1016\/j.therap.2026.03.004_bib0175","unstructured":"Haute autorit\u00e9 de sant\u00e9. Prise en charge du patient pr\u00e9sentant une lombalgie commune. 2019. https:\/\/www.has-sante.fr\/jcms\/c_2961499\/fr\/prise-en-charge-du-patient-presentant-une-lombalgie-commune. [Consult\u00e9 le 31\u00a0mars 2026]."},{"key":"10.1016\/j.therap.2026.03.004_bib0180","doi-asserted-by":"crossref","first-page":"514","DOI":"10.7326\/M16-2367","article-title":"Noninvasive treatments for acute, subacute, and chronic low back pain: a clinical practice guideline from the American College of Physicians","volume":"166","author":"Qaseem","year":"2017","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.therap.2026.03.004_bib0185","doi-asserted-by":"crossref","first-page":"n1446","DOI":"10.1136\/bmj.n1446","article-title":"Efficacy, acceptability, and safety of muscle relaxants for adults with non-specific low back pain: systematic review and meta-analysis","volume":"374","author":"Cashin","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.therap.2026.03.004_bib0190","unstructured":"Th\u00e9riaque. 2026. https:\/\/www.theriaque.org\/apps\/recherche\/rch_simple.php#. [Consult\u00e9 le 31\u00a0mars 2026]."},{"key":"10.1016\/j.therap.2026.03.004_bib0195","unstructured":"VIDAL. M\u00e9thocarbamol\u00a0: substance active \u00e0 effet th\u00e9rapeutique. 2013. https:\/\/www.vidal.fr\/medicaments\/substances\/methocarbamol-2344.html. [Consult\u00e9 le 31 mars 2026]."},{"key":"10.1016\/j.therap.2026.03.004_bib0200","unstructured":"VIDAL. Thiocolchicoside\u00a0: substance active \u00e0 effet th\u00e9rapeutique. 2015. https:\/\/www.vidal.fr\/medicaments\/substances\/thiocolchicoside-3494.html. [Consult\u00e9 le 31\u00a0mars 2026]."},{"key":"10.1016\/j.therap.2026.03.004_bib0205","unstructured":"Paitraud D. VIDAL. 2017. D\u00e9remboursement des thiocolchicosides oraux (COLTRAMYL et g\u00e9n\u00e9riques) \u00e0 compter du 2\u00a0janvier 2018. https:\/\/www.vidal.fr\/actualites\/22429-deremboursement-des-thiocolchicosides-oraux-coltramyl-et-generiques-a-compter-du-2-janvier-2018.html. [Consult\u00e9 le 31\u00a0mars 2026]."},{"key":"10.1016\/j.therap.2026.03.004_bib0210","unstructured":"ANSM. \u00c9tat des lieux de la consommation de benzodiaz\u00e9pines en France. D\u00e9cembre 2013. https:\/\/uspo.fr\/wp-content\/uploads\/2014\/01\/ANSM_Rapport%20Benzo_08012014.pdf. [Consult\u00e9 le 31\u00a0mars 2026 (82\u00a0pp.)]."},{"key":"10.1016\/j.therap.2026.03.004_bib0215","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.therap.2022.10.008","article-title":"Project rebuild the evidence base (REB): a method to interpret randomised clinical trials and their meta-analysis to present solid benefit-risk assessments to patients","volume":"78","author":"Boussageon","year":"2023","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2026.03.004_bib0220","unstructured":"PRISMA. PRISMA statement 2020. 2020. https:\/\/www.prisma-statement.org\/prisma-2020-statement. [Consult\u00e9 le 31\u00a0mars 2026]."},{"key":"10.1016\/j.therap.2026.03.004_bib0225","unstructured":"World Health Organization. International classification of functioning, disability and health (ICF). 2025. https:\/\/www.who.int\/standards\/classifications\/international-classification-of-functioning-disability-and-health. [Consult\u00e9 le 31\u00a0mars 2026]."},{"key":"10.1016\/j.therap.2026.03.004_bib0230","unstructured":"Cochrane Consumers and Communication La Trobe University, Ryan R, Hill S. How to GRADE. 25\u00a0juill 2018. https:\/\/opal.latrobe.edu.au\/articles\/journal_contribution\/How_to_GRADE\/6818894\/1. doi:10.26181\/5b57d95632a2c.[Consult\u00e9 le 31\u00a0mars 2026]."},{"key":"10.1016\/j.therap.2026.03.004_bib0235","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/S1297-319X(03)00075-7","article-title":"Multicenter, randomized, double-blinded, placebo-controlled trial of thiocolchicoside in acute low back pain","volume":"70","author":"T\u00fcz\u00fcn","year":"2003","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.therap.2026.03.004_bib0240","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1111\/j.1742-1241.2004.00454.x","article-title":"Assessment of efficacy and psychomotor performances of thiocolchicoside and tizanidine in patients with acute low back pain","volume":"59","author":"Ketenci","year":"2005","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.therap.2026.03.004_bib0245","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.annemergmed.2016.10.002","article-title":"Diazepam is no better than placebo when added to naproxen for acute low back pain","volume":"70","author":"Friedman","year":"2017","journal-title":"Ann Emerg Med"},{"key":"10.1016\/j.therap.2026.03.004_bib0250","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.annemergmed.2017.09.031","article-title":"A randomized, double-blind, placebo-controlled trial of naproxen with or without orphenadrine or methocarbamol for acute low back pain","volume":"71","author":"Friedman","year":"2018","journal-title":"Ann Emerg Med"},{"key":"10.1016\/j.therap.2026.03.004_bib0255","first-page":"303","article-title":"Diazepam in backache. A double-blind controlled trial","volume":"8","author":"Hingorani","year":"1966","journal-title":"Ann Phys Med"},{"key":"10.1016\/j.therap.2026.03.004_bib0260","first-page":"1133","article-title":"Evaluation of thiocolchicoside as monotherapy in low back pain. Results of a randomized study versus placebo","volume":"19","author":"Marcel","year":"1990","journal-title":"Presse Med"},{"key":"10.1016\/j.therap.2026.03.004_bib0265","doi-asserted-by":"crossref","first-page":"96","DOI":"10.4103\/jrpp.JRPP_21_31","article-title":"Efficacy of the combination of indomethacin and methocarbamol versus indomethacin alone in patients with acute low back pain: a double-blind, randomized placebo-controlled clinical trial","volume":"10","author":"Samsamshariat","year":"2021","journal-title":"J Res Pharm Pract"},{"key":"10.1016\/j.therap.2026.03.004_bib0270","doi-asserted-by":"crossref","first-page":"456","DOI":"10.5606\/tftrd.2022.9744","article-title":"A multi-center, double-blind, randomized parallel-group Phase IV study comparing the efficacy and safety of thiocolchicoside ointment versus placebo in patients with chronic mechanical low back pain and an acute muscle spasm","volume":"68","author":"Ketenci","year":"2022","journal-title":"Turk J Phys Med Rehabil"},{"key":"10.1016\/j.therap.2026.03.004_bib0275","series-title":"Analgesic effects of non-surgical and non-interventional treatments for low back pain: a systematic review and meta-analysis of placebo-controlled randomised trials.","author":"Cashin","year":"2025"},{"key":"10.1016\/j.therap.2026.03.004_bib0280","doi-asserted-by":"crossref","first-page":"6133","DOI":"10.3390\/jcm13206133","article-title":"Efficacy of thiocolchicoside for musculoskeletal pain management: a systematic review and meta-analysis of randomized controlled trials","volume":"13","author":"Bianconi","year":"2024","journal-title":"J Clin Med"},{"key":"10.1016\/j.therap.2026.03.004_bib0285","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.jclinepi.2014.12.017","article-title":"Using data sources beyond PubMed has a modest impact on the results of systematic reviews of therapeutic interventions","volume":"68","author":"Halladay","year":"2015","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.therap.2026.03.004_bib0290","unstructured":"Cochrane Library. Cochrane Central Register of Controlled Trials. EUCTR2021-000067-68-IT. Efficacy and safety of different dosage regimens of the combination methocarbamol\/paracetamol in acute Low Back Pain (LBP): mioPain study. 2021. https:\/\/www.cochranelibrary.com\/central\/doi\/10.1002\/central\/CN-02329192\/full. [Consult\u00e9 le 31 mars 2026]."},{"key":"10.1016\/j.therap.2026.03.004_bib0295","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/bmj.312.7023.71","article-title":"Evidence based medicine: what it is and what it isn\u2019t","volume":"312","author":"Sackett","year":"1996","journal-title":"BMJ"},{"key":"10.1016\/j.therap.2026.03.004_bib0300","doi-asserted-by":"crossref","first-page":"n2321","DOI":"10.1136\/bmj.n2321","article-title":"Effectiveness and safety of non-steroidal anti-inflammatory drugs and opioid treatment for knee and hip osteoarthritis: network meta-analysis","volume":"375","author":"da\u00a0Costa","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.therap.2026.03.004_bib0305","first-page":"614","article-title":"Do Patients with acute low back pain in emergency departments have more severe symptoms than those in general practice? A systematic review with meta-analysis","volume":"23","author":"Oliveira","year":"2022","journal-title":"Pain Med Malden Mass"},{"key":"10.1016\/j.therap.2026.03.004_bib0310","unstructured":"Haute autorit\u00e9 de sant\u00e9. Prise en charge du patient pr\u00e9sentant une lombalgie commune. 2019. https:\/\/www.has-sante.fr\/jcms\/c_2961499\/fr\/prise-en-charge-du-patient-presentant-une-lombalgie-commune. [Consult\u00e9 le 31 mars 2026]."},{"key":"10.1016\/j.therap.2026.03.004_bib0315","unstructured":"ANSM. Suspension des autorisations de mise sur le march\u00e9 du t\u00e9traz\u00e9pam (Myolastan et ses g\u00e9n\u00e9riques) - Point d\u2019Information. 2013. https:\/\/archive.ansm.sante.fr\/S-informer\/Points-d-information-Points-d-information\/Suspension-des-autorisations-de-mise-sur-le-marche-du-tetrazepam-Myolastan-et-ses-generiques-Point-d-Information. [Consult\u00e9 le 31\u00a0mars 2026]."},{"key":"10.1016\/j.therap.2026.03.004_bib0320","unstructured":"ANSM. Information de s\u00e9curit\u00e9 - Sp\u00e9cialit\u00e9s contenant du thiocolchicoside. Rappels et recommandations concernant le risque potentiel de g\u00e9notoxicit\u00e9. F\u00e9vrier 2025. https:\/\/ansm.sante.fr\/informations-de-securite\/specialites-contenant-du-thiocolchicoside-rappels-et-nouvelles-recommandations-concernant-le-risque-potentiel-de-genotoxicite. [Consult\u00e9 le 31\u00a0mars 2026]."},{"key":"10.1016\/j.therap.2026.03.004_bib0325","doi-asserted-by":"crossref","first-page":"e2434835","DOI":"10.1001\/jamanetworkopen.2024.34835","article-title":"Long-term use of muscle relaxant medications for chronic pain: a systematic review","volume":"7","author":"Oldfield","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.therap.2026.03.004_bib0165","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr7103a1","article-title":"CDC Clinical practice guideline for prescribing opioids for pain \u2014 United States, 2022","volume":"71","author":"Dowell","year":"2022","journal-title":"MMWR Recomm Rep"}],"container-title":["Therapies"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004059572600051X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004059572600051X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T19:50:08Z","timestamp":1793217008000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S004059572600051X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S004059572600051X"],"URL":"https:\/\/doi.org\/10.1016\/j.therap.2026.03.004","relation":{},"ISSN":["0040-5957"],"issn-type":[{"value":"0040-5957","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Revue syst\u00e9matique de la litt\u00e9rature et \u00e9valuation de l\u2019efficacit\u00e9 des myorelaxants dans les lombalgies aigu\u00ebs selon la m\u00e9thode REB","name":"articletitle","label":"Article Title"},{"value":"Therapies","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.therap.2026.03.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Masson SAS on behalf of Soci\u00e9t\u00e9 fran\u00e7aise de pharmacologie et de th\u00e9rapeutique.","name":"copyright","label":"Copyright"}]}}